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Available online 1 October 2016Background:Mechanical stretch, in term of skin expansion, can induce effective but limited in vivo skin regener-
ation for complex skin defect reconstruction.We propose a strategy to obtain regenerated skin by combining au-
tologous stem cell transplantation with mechanical stretch.
Methods: This randomized, blinded placebo-controlled trial enrolled 38 adult patients undergoing skin expansion
presenting with signs of exhausted regenerative capacity. Patients randomly received autologous bone marrow
mononuclear cell (MNC) or placebo injections intradermally. Follow-up examinations were at 4, 8 weeks and
2 years. The primary endpoint was the volume achieved in relation to the designed size of the expander (expan-
sion index, EI). Secondary endpoints were surface area, thickness and texture of expanded skin. This trial is reg-
istered with ClinicalTrial.gov, NCT01209611.
Findings: The MNC group had a signiﬁcantly higher EI at 4 weeks (mean difference 0.59 [95% CI, 0.03–1.16]; p =
0.039) and 8 weeks (1.05 [95% CI, 0.45–1.66]; p= 0.001) versus controls. At 8 weeks, theMNC group had signif-
icantly thicker skin (epidermis: p b 0.001, dermis: p b 0.001) and higher subjective scores for skin quality/texture
(24.8 [95% CI, 17.6–32.1]; p b 0.001). The MNC group had more skin surface area (70.34 cm2 [95% CI, 39.75–
100.92]; p b 0.001). Patients in the MNC group gained up to the quadrupled surface area of expanded skin com-
pared to pre-expansion at the end of expansion. No severe adverse events occurred.
Interpretation: Intradermal transplantation of autologous stem cells represents a safe and effective strategy to
promote in vivo mechanical stretch induced skin regeneration, which can provide complex skin defect recon-
struction with plentiful of tissue.






Bone mononuclear cells1. Introduction
Skin losses as results of a number of common diseases and injuries
affect over 11 million people worldwide annually (Clark et al., 2007;
Peck, 2011). Repairingmassive skin deﬁciencies remains as amajor clin-
ical challenge, due to lack of suitable cutaneous tissue. Mechanical
stretch is a stimulus that can initiate both in vivo and in vitro cell prolif-
eration and regeneration (Mihic et al., 2014; Li et al., 2013). The clinical
application of mechanical stretch, skin expansion, is a reliableeconstructive Surgery, Shanghai
ool of Medicine, 639 Zhizaoju
pen access article under the CC BY-Nreconstructive method for complex wounds. Constant mechanical
stretch induced by inﬂating silicone expander stimulates in vivo skin re-
generation (Handschel et al., 2013) that creates additional well-
vascularized cutaneous tissue that is well-matched to the color, texture
and contour of surrounding skin (Weng et al., 2010; Xie et al., 2013).
Often times in large area of tissue reconstruction, more skin is need-
ed for reconstruction than tissue expansion can provide, because skin
does not have the growth capacity to be expanded beyond two to
three times its original area. Overexpansion results in thin, poorly
vascularized tissue, which leads to skin necrosis and reconstructive fail-
ure (Huang et al., 2011; Elshahat, 2011). Bone marrow stem cell thera-
pies have showed promise in promoting tissue regeneration, as
applications have been reported in wound healing, critical limb ische-
mia, bone growth and cardiac tissue remodelling (Backly andC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical trial protocol.
42 patients assessed for 
eligibility
38 patients randomized
4 excluded for lack 
of consent
19 randomized to MNC 
group (treatment group)
19 randomized to control 
group
19 assessed for primary 
outcome at 8 weeks
19 assessed for primary 
outcome at 8 weeks
357S.-B. Zhou et al. / EBioMedicine 13 (2016) 356–364Cancedda, 2010; Liu et al., 2012). We proposed the hypothesis that the
transplantation of stem cells could possibly promotemechanical stretch
induced skin regeneration and mitigate traditional limitations of skin
expansion. Our recent preclinical ﬁndings supported this hypothesis
(Yang et al., 2011). Additionally, combining mechanical stretch and
stem cell transplantation for skin regeneration may wider the clinical
implications for other types of in vivo tissue regeneration.
In this phase 1/2 trial, we aimed to evaluate the safety and efﬁcacy of
intradermal injection of autologous bone marrow mononuclear cells




This 2-year study was a parallel, randomized, blinded, placebo-
controlled clinical trial.
The study consisted of two phases. Phase 1, the pilot,was used to de-
termine the sample size for Phase 2 and randomized 10 patients (5 to
treatment and 5 to control). It showed that with 15 patients per study
arm, the statistic power would be N90% (two-sided, alpha = 0.05). As-
suming an attrition rate of 25% over the course of the study, we totally
enrolled 38 patients (19 per group.)
2.2. Patients
The recruitment began onMarch 8th, 2011. Eligible patientswere 18
to 60 years of age, had received surgical placement of an expander on
the face, neck, anterior chest wall, abdominal wall or back that had
been inﬂated to volumes of 80 to 600 cm3. All patients had deterioration
in expanded skin texture and thin/papery skin overlying the expander
that did not improve after a 2 weeks' suspension of expansion, had ele-
vated pressures in the tissue expander for at least 2 weeks, and needed
further skin expansion to complete reconstruction. All patients were
assessed by two independent plastic surgeons for eligibility.
Exclusion criteria included a history of severe illnesses, including any
cancers, hepatitis, coronary artery disease, arteriosclerosis, diabetes,
obesity (BMI N 30), anemia, myelodysplastic syndromes, and a history
of bonemarrow transplantation. Patients with risk factors for tissue ne-
crosis such as steroid use and smoking within the previous 6 months
were excluded.
2.3. Randomization and Masking
After patients signed the informedwritten consent forms, theywere
randomized into two study groups, the MNC Group and the Control
Group, in a 1:1 ratio by a computer-generated randomization schedule.
The patient recruiting team randomized participants along the schedule
and the conduct team performed the assigned treatment. Participants,
data collectors, laboratory staff were masked during the trial. See
Table 1 for the trial proﬁle.
2.4. Intervention and Tissue Expansion Protocol
After randomization, the treatment group had bonemarrowaspirate
harvested from the anterior iliac crest under general or local anesthesia.
MNCs were isolated using density gradient centrifugation (COBE 2991
Cell Processor, Gambro BCT, Lakewood, CO). An automated
haemocytometer was used to conﬁrm uniform cell counts in each
MNC preparation; nucleated cell viability was assessed using trypan
blue exclusion. The cell suspension including a total of 2.4–12.5 × 107
cells was adjusted to a ﬁnal volume of 6–20mlwith saline. The ﬂow cy-
tometry analysis showed that MNCs samples contained an average of
2.37% CD34 cells, 0.92% CD90 cells, 3.51% CD105 cells and 0.95%
CD133 cells. Approximately 0.1 ml cell suspension was injectedintradermally into per cm2 expanded skin via a 27-gauge needle (ap-
proximately 0.5–1 × 106 cells/cm2). An equal volume of saline was
injected in the control group.
All patients continuedwith expander inﬂation immediately after cell
transplantation, every three days to a target inner pressure of
100 mmHg. The inner pressure of the tissue expander was measured
during each inﬂation,with the inner pressuremeter reported previously
(Sheng et al., 2013). The inﬂation stopped while the inner pressure of
expander reached 100 mmHg. Inﬂation continued for at least 8 weeks,
until sufﬁcient tissue for reconstruction was obtained, or until skin
had reached its maximal regenerative capacity. At that point, the ex-
panded ﬂap was surgically transferred to the recipient site.
2.5. Assessment and End Points
Outcomes were assessed at baseline (immediately before treat-
ment) and 4weeks, 8weeks and two years after treatment. The primary
end point was the absolute change in the expansion index measured at
4 weeks and 8 weeks after treatment. Secondary end points were
changes in skin surface area, thickness and texture at 8 weeks versus
baseline. Safety evaluations were conducted at two years.
2.5.1. Expansion Index (EI)
The volumes inﬂated at each visit were summed to obtain the total
inﬂation volume. Each patient's tissue expander had a slightly different
maximum capacity. To account for these sizes differences,we calculated
an expansion index (EI), the total volume inﬂated divided by the de-
signed volume of the expander.
2.5.2. Expanded Skin Surface Area
Before treatment and at 8 weeks post-treatment, all patients
underwent 3-dimenssional laser scanning (Vivid 910, Minolta, Japan,
with RapidForm 2006 software, INUS Technology) to measure the ex-
panded skin's surface area. The surface area gained during the treatment
phase was calculated by comparing the surface area at baseline versus
8 weeks.
2.5.3. Expanded Skin Thickness
The epidermal and dermal thicknesses of the expanded skin were
measured at eight evenly spaced, marked points along the longitudinal
axis using a duplex ultrasonic scanner (GE E8, 14 MHz) at baseline,
4 weeks and 8 weeks. Epidermal thickness was deﬁned as the distance
between the air-epidermal and epidermal-dermal high echo-level
Table 2
Demographic and baseline characteristics of patients.






Age in years, mean(SD) 34.32(12.73) 34.89(12.86)
Male 15 78.95 14 73.68
Smoker (last 6 months) 5 26.32 6 31.58
Cause of defect
Post-burn scar 17 89.47 18 94.74
Nevus 2 10.53 1 5.26
Site of expanded skin
Face 4 21.05 5 26.32
Neck 7 36.84 4 21.05
Trunk 8 42.11 10 52.63




Maximum size of tissue
expander(ml)
b100 2 10.53 3 15.79
100–250 9 47.37 9 47.37
N250 8 42.11 7 36.84
Previous expansion at the same
site
None 13 68.42 15 78.95









Papery 13 68.42 11 57.89
Stretch marks 4 21.05 7 36.84
Consistent High Inner
Pressure
3 15.79 2 10.53
a Unless otherwise deﬁned.
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epidermal-dermal and dermal-subdermal high echo-level bands.
2.5.4. Expanded Skin Quality/Texture
We constructed a Visual Analogue Scale (VAS) for patients to self-
assess the texture of their expanded skin (Paul-Dauphin et al., 1999).
The left anchor of the VAS was set as “signiﬁcantly deteriorated” and
the right anchor was set as “signiﬁcantly improved”. All patients
assessed the texture of their expanded skin at baseline, 4 weeks and
8 weeks.
2.5.5. Histological Examination
Tissue specimens were harvested during ﬂap transfer surgery and
included the expanded skin with adjacent unexpanded skin. Specimens
were ﬁxed with 4% paraformaldehyde and embedded in parafﬁn. 6 μm
sections were stained with hematoxylin-eosin (H&E) and immunohis-
tochemistrywith an anti-PCNA antibodywas used to identify proliferat-
ing cells. The number of PCNA-positive cells was counted in 5 random
high-power ﬁelds (HPFs, 400X) using laser scanning confocal microsco-
py (Leica, Germany). Anti-CD31 antibody was applied to evaluate skin
vascularization.
2.5.6. Safety
At two-years post treatment, all patients were brought to the clinic
for a complete blood count with differential, history and physical exam.
2.6. Study Oversight
This study, registered with ClinicalTrial.gov (number
NCT01209611), was approved by the institutional review board of
Shanghai Ninth People's Hospital and conducted in accordance with
the Declaration of Helsinki. Sponsors had no role in the study design,
data collection, data analysis, data interpretation, or writing of this
report.
2.7. Statistical Analysis
Continuous variables are presented as mean(standard deviation),
unless noted. Categorical variables are presented as counts and percent-
ages. Chi-squared and Student's t-tests were used to compare groups.
Analysis of end points was performed on an intention-to-treat basis.
Fisher's Exact Test was used when expected values of the cell counts
were low while evaluating group associations at different time points.
Safety analysis was conducted for all patients who had undergone ran-
domization and treatment. The repeated-measure linear model was
used to identify changes in the continuous variables over time for
each group. Signiﬁcance was set at alpha b 0.05. SPSS (version 16.0)
was used for analyses.
3. Results
3.1. Patient Characteristics
Of the 42 patients recruited between March 2011 and March 2013,
four were excluded because of refusing to sign inform consent. 38 pa-
tients were enrolled, with 19 randomly assigned to treatment and 19
to placebo. No patient dropout occurred after randomization. BaselineFig. 1. Changes in the EI and expansion volume. TheMNC group had signiﬁcant an increase in EI
p b 0.001, respectively (B). The increase in total inﬂation volume in treatment versus control g
deteriorated in thickness and quality. At 8 weeks, photographs show a signiﬁcant increase in
reconstruction (E). Patient 2: prior to study enrollment, the patient had stretch marks throu
After MNC injection, stretch marks diminished and skin growth improved. Photographs sho
which continued to grow for an additional 16 weeks. At the end of the expansion process, t
Patient 3: case from the Control Group. The patient presented with stretch marker at the b
markers (*p = 0.039, **p b 0.001).demographic and disease characteristicswere not signiﬁcantly different
between the groups (Table 2).3.2. Primary Outcomes
The treatment group had signiﬁcantly higher EI versus controls at
4 weeks (mean difference 0.59 [95% CI 0.03–1.16]; p = 0.039) and
8 weeks (mean difference 1.05 [95% CI 0.45–1.66]; p = 0.001) (Fig. 1).
At baseline, patients from both groups had similar expander inﬂation
volumes (595.39(464.97) ml vs. 533.82(369.14) ml, p = 0.65) and EIs
(2.55(0.86) vs. 2.44(0.68), p = 0.67). At 4 weeks post treatment, pa-
tients in the treatment group had a total inﬂation volume of
771.63(594.13) ml and EI of 3.36(1.00), versus patients in the control
group with a total inﬂation volume of 595.55(392.19) ml and EI of
2.76(0.69). At 8 weeks post treatment, the treatment group had an in-
ﬂation volume and EI of 920.95(688.70) ml and 4.05(1.06), respective-
ly; the control group had inﬂation an expansion volume and EI of
640.68(412.69) ml and 3.00 (0.74), respectively (Fig. 1).
All patients from the treatment groupwere able to continue expand-
er inﬂation longer than 4 weeks (Fig. 1), whereas only 5 patients in the
in control group were able to do so.at both 4 and 8weeks. (A), higher EI than the control group at 4 and8weeks. p=0.039 and
roups was showed (C–D). Patient 1: prior to enrollment, this patient's expanded skin had
the expanded skin surface area and quality, and was successfully used for face and neck
ghout the expanded skin and could not continue expansion due to thinness of the skin.
w a signiﬁcant increase in the expanded skin surface area at 8 weeks after treatment,
he donor site skin had quadrupled in surface area, from 15 ∗ 13 cm2 to 35 ∗ 32 cm2 (F).
aseline. At 8 weeks, the expanded skin became deteriorated with more severe stretch
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Fig. 2. Evaluation of skin surface area and texture. The expanded skin surface at baseline (A) and 8 weeks (B) was evaluated by 3-Dimensional laser scanning. The results showed that the
MNC group had signiﬁcantlymore skin surface area at 8weeks versus controls (p b 0.001), despite startingwith similar amounts of skin surface area at baseline (p=0.612) (C). Patients in
theMNC group gained signiﬁcantlymore skin surface area after 8weeks of treatment (D). Photographs show signiﬁcant improvement in expanded skin texture at 4weeks post treatment
compared to baseline. E G, I, before treatment; F, H, J, 4 weeks post treatment. Patients in theMNC group scored higher in their assessment of their expanded skin quality versus patients in
the control group at both 4 weeks and 8 weeks (*p b 0.001).
360 S.-B. Zhou et al. / EBioMedicine 13 (2016) 356–3643.3. Secondary Outcomes
3.3.1. Surface Area of Expanded Skin
3D scanning indicated that patients in the treatment group had sig-
niﬁcant increases in expanded skin surface area compared to the control
group (Fig. 2). At baseline, the expanded skin surface of the treatment
and control groups were 241.30(141.42) cm2 and 219.19(124.44) cm2,
respectively (p = 0.612). At 8 weeks, skin surface area increased to
357.41(194.40) cm2 in the treatment group (an increase of
116.11(58.69)cm2) and 265.96(138.81)cm2 in the control group (an in-
crease of 45.77(27.48)cm2) (mean difference 70.34 cm2 [95% CI, 39.75–
100.92]; p b 0.001).3.3.2. Skin Texture
The treatment group had higher VAS scores at 4 weeks (79.0(8.4)
versus 54.2(11.6)) in the control group (mean difference 24.8 [95% CI,
18.2–31.5]; p b 0.001). The MNC group continued to score higher at
8 weeks (69.8(11.2) versus 45.0(10.7) in the control group, meandifference 24.8 [95% CI, 17.6–32.1]; p b 0.001). Fig. 2 highlights im-
proved skin textures in the MNC group at their 4-week assessment. At
8weeks, signiﬁcantly fewer patients in the treatment group complained
of thin, papery/transparent skin versus controls (1 versus 7, p = 0.04).
3.3.3. Skin Thickness
The MNC group had signiﬁcantly thicker epidermis and dermis ver-
sus controls at 4 weeks (epidermal mean difference of 0.06mm [95% CI,
0.04–0.08]; p b 0.001; dermalmeandifference of 0.36mm[95%CI, 0.15–
0.57]; p b 0.001) and 8 weeks (epidermal mean difference of 0.05 mm
[95% CI, 0.03–0.08]; p b 0.001; dermal mean difference of 0.42 mm
[95% CI, 0.22–0.62]; p b 0.001).
At baseline, the MNC and the control groups had similar epidermal
and dermal thicknesses (epidermis: 0.16(0.03) mm and 0.17(0.02) mm,
respectively (p = 0.526); dermis: 0.75(0.33)mm and 0.74(0.32)mm, re-
spectively (p= 0.91)). At 4 weeks, the epidermal thickness of treatment
patients increased by 0.04(0.03) mm to 0.21(0.03) mm (p b 0.001),
and the dermal thickness increased 0.31(0.12) mm to 1.01(0.38) mm
(p = 0.029). Improvement continued at 8 weeks: epidermal thickness
Fig. 3. Thickness of expanded skin in each group over time. Ultrasoundwas used to assess the thickness of the expanded skin in both groups (A–C, results from theMNC group at baseline,
4 weeks, and 8 weeks). Epidermal thickness in the treatment group increased signiﬁcantly at 4 weeks and 8 weeks, whereas the epidermal thickness in the control group steadily
decreased (D). A similar downward trend was found in dermal thickness at 4 and 8 weeks for the control group (E) (*p b 0.001, **p = 0.029, †p = 0.076, ‡p = 0.017).
361S.-B. Zhou et al. / EBioMedicine 13 (2016) 356–364in the MNC group was 0.19(0.04) mm (a 0.03(0.03) mm increase from
baseline (p b 0.001)), and dermal thickness was 0.95(0.38) mm, (a
0.23(0.14) mm increase from baseline (p = 0.076)) (Fig. 2).
In controls, both the epidermis and the dermis decreased in thick-
ness throughout follow-up: the epidermis was 0.15(0.03) mm at
4weeks (p b 0.001) and 0.14(0.03)mm at 8weeks (p b 0.001); the der-
malwas 0.65(0.24)mmat 4weeks (p=0.36) and 0.52(0.19)mm (p=
0.017) at 8 weeks (Fig. 3).Fig. 4.Histology of expanded skin. HE staining andMasson stainingwas used to examine the exp
epidermis and dermis versus the control group (B, D). The results showed that skin sections fr
epidermal and dermal thickness (E–F) (*p b 0.001).3.3.4. Histological Examination
OnHE staining, skin samples from theMNC groupwere thicker than
those of the control group. Epidermal thickness of in the MNC group
was 0.17(0.03) mm versus 0.10(0.02)mm in the control group (mean
difference 0.07 mm [95% CI, 0.05–0.08]; p b 0.001). Dermal thickness
in the treatment group was 3.21(0.52) mm versus 1.51(0.45) mm in
the control group (mean difference 1.58 mm [95% CI, 1.50–2.14];
p b 0.001) (Fig. 4). Due to elastic contraction of the skin after expanderanded skin sections fromeach group. The treatment group (A, C), had signiﬁcantly thicker
om the MNC Group were signiﬁcantly thicken than those from the Control Group in both
362 S.-B. Zhou et al. / EBioMedicine 13 (2016) 356–364removal, dermal thickness was higher on histological analysis than ul-
trasound examination in all patients.
The MNC group had signiﬁcantly more PCNA+ proliferating cells in
the basal layer of the epidermis (p = 0.001), and superior vasculariza-
tion as shown by more CD31+ cells in skin sections (p b 0.001) versus
controls (Fig. 5).
3.3.5. Safety
During the study, one patient in the MNC group had their expander
damaged via puncture during routine inﬂation. The expander was im-
mediately replaced and the patient completed the trial by successfully
completing expander inﬂation and follow-up. Temporary ecchymosis
within the injected treatment area was observed in all patients in both
groups. This effect resolvedwithin oneweekwithout residual complica-
tions. During the 8-week follow-up, no infection occurred, and no se-
vere adverse events, such as ectopic mass formation, skin ulceration,
or necrosis, were observed.
At the two-year follow-up blood test and physical exam, no patients
had anemia, leukopenia or other signs of hematopoietic suppression.
4. Discussion
Large-scale skin deformity reconstruction remains a challenge in
plastic surgery due to the lack of adequate adnexal soft tissue and
skin. Our trial is to synergistically combine twomethods of regenerativeFig. 5. Immunohistochemical staining of expanded skin. Staining showed thatmore PCNA+ cel
(B). Statistical analyses showed that the PCNA+ cell number was signiﬁcantly higher in trea
expanded skin from the treatment group (D) compared to the control group (E), indicating su
was signiﬁcantly higher in MNC Group compared with the Control Group (F). Bar, 25 μm (*p btissue stimuli, stem cells and mechanical stretch, to overcome the limi-
tations of stretch-induced regeneration and create autologous tissue.
Mechanical stretch via tissue expanders stimulates proliferation and
maturation in both embryonic and adult cells (Mihic et al., 2014;
Banerjee et al., 2015). In adult skin, mechanical tension induces ﬁbro-
blasts proliferation and collagen synthesis (Wong et al., 2012) while
mechanotransduction can induce epithelial morphogenesis and
wound healing (Wong et al., 2012; Zhang et al., 2011). Skin expanders
use mechanical stretch to stimulate cell proliferation and activate ﬁbrin
and collagen synthesis to achieve in vivo regeneration of overlaying skin
(Jaalouk and Lammerding, 2009; Zollner et al., 2013). However, the re-
generative capacity of skin is limited. Mechanism for regenerative ex-
haustion in skin is still debated and previous attempts to sustain
in vivo tissue regeneration using single growth factors have been inef-
fective (Sun et al., 2014). Recent ﬁndings suggest that stem cell deregu-
lation or insufﬁciency is involved (Clevers et al., 2014; Pellettieri and
Sanchez, 2007). Our recent preclinical studies showed that mechanical
stretch in skin can recruit circulating bone marrow-derived stem cells
migrating and participating in skin regeneration (Zhou et al., 2013;
Zhou et al., 2014). Results also proved intradermal transplantation of
bone marrow-derived stem cells to stretched rat skin effectively en-
hances skin growth (Yang et al., 2011).
MNC is a group of cells including multiple kinds of stem/progenitor
cells, including bonemarrowmesenchymal cells and epithelial progen-
itor cells, which have demonstrated a regenerative promoting effect
(Assmus et al., 2006; Tateishi-Yuyama et al., 2002; Perin et al., 2012).ls were observed in expanded skin from theMNC group (A) compared to the control group
tment group compared with the control group (C). More CD31+ cells were observed in
perior angiogenesis in the treatment group. Results showed that the PCNA+ cell number
0.001, **p = 0.001).
363S.-B. Zhou et al. / EBioMedicine 13 (2016) 356–364According to current studies, MNCs can secrete a wide spectrum of
growth factors (Otsuru et al., 2012; Moniche et al., 2012; Usach et al.,
2011) and clinical efﬁcacy of MNC-assisted tissue regeneration has
been found in boney (Otsuru et al., 2012), neural (Moniche et al.,
2012; Usach et al., 2011) and cardiac tissue (Perin et al., 2012;
Goncharova et al., 2014), likely through microenvironment regulation
(Backly and Cancedda, 2010; Stappenbeck and Miyoshi, 2009;
Laﬂamme and Murry, 2011). Moreover, the safety of MNC transplanta-
tion has been veriﬁed in these clinical trials, making MNCs transplanta-
tion a reliable option for clinical application. The minimal ex vivo
manipulation of MNCs separation makes it feasible for use. In this trial,
we discussed the application ofMNCs transplantation in stimulating au-
tologous tissue regeneration under mechanical stretch.
Results from this study indicate that intradermal transplantation of
MNCs in humans can promote sustainable regeneration ofmechanically
stretched skin that had previously shown signs of regenerative exhaus-
tion. The MNC group showed statistically signiﬁcant improvement ver-
sus both controls and baseline for all primary and secondary outcomes.
Surface area of expanded skin in the treatment group grew 48% from
baseline, which was twice as much as controls. Our evidence showed
that intradermal MNC injections reverse the trajectory of skin thinning
and deteriorating texture while continuing skin expansion in patients
who had reached regenerative exhaustion.
Though several experimental approaches have explored suitable
biomaterials and tissue-engineering technologies for full-thickness
skin reconstruction, limited clinical successes have been achieved (Sun
et al., 2014; Russell, 2014). Our attempt to conjunct stem cell with
in vivo mechanical stretch has broad implications for safer, larger-
scale skin reconstruction. Mechanical stretch during tissue expansion
creates a unique microenvironment (Zollner et al., 2013; Zhou et al.,
2013) for skin regeneration. With the assist of MNCs, stretched skins
are endorsed accelerated angiogenesis (Sheng et al., 2011; Zhou et al.,
2013; Sasaki et al., 2008) and growth factor secretion (Yang et al.,
2011; Stappenbeck andMiyoshi, 2009). Histological results of the pres-
ent trial showed that therewas a durable increase in the number of pro-
liferating cells in the expanded skin after MNC transplantation
(p b 0.01). Further investigations are required to understand the thera-
peutic mechanism by which MNCs promote cell proliferation and re-
generation. Limitations of our study include the small sample size, as
larger, multi-center trials are warranted.While the safety of MNC trans-
plantation has been veriﬁed in clinical trials (Assmus et al., 2006;
Assmus et al., 2007; Perin et al., 2011), longer-term follow-up in our co-
hort is needed and underway to assess safety and long-term results.
More accessible autologous stem cells are needed; as such, we are cur-
rently evaluating the efﬁcacy of more readily harvested stem cells,
such as adipose derived stem cells. Deﬁning contraindications for this
type of therapy are important for translational purposes. Cancer pa-
tients comprise an important subset of patients requiring large-scale re-
construction; the safety of using stem cells in close proximity to a
previously cancerous area must be investigated. Finally, the cellular
mechanism by which the transplanted MNCs accelerate skin regenera-
tion under stretch must be further explored. Our histological results
showed signiﬁcantly more proliferating cells and angiogenesis in the
treatment group, but we could not track transplanted stem cells.
In conclusion, our study shows that intradermally transplanted
MNCs inmechanical stretched skin is a safe and feasible clinical applica-
tion that can overcome the regenerative limitations of skin to provide
signiﬁcant amounts tissue for surgical reconstruction. We believe that
synergistically integrating stem cells and mechanical stretch stimuli
will engender further advances in in vivo tissue regeneration.
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